Stay updated on Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe web page now includes a service alert about planned maintenance starting July 25th, which will affect service availability for over 24 hours. Additionally, the version has been updated from v2.16.4 to v2.16.5.SummaryDifference2%
- Check27 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check49 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check56 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
Stay in the know with updates to Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.